nan
Artificial Intelligence-Powered Supplier Risk Management Market Size, Value And Growth Trends Through 2030
The glucagon-like peptide-1(GLP-1) cardiometabolic expansion market has demonstrated rapid growth in its size during recent years. Anticipated growth shows it moving from $51.8 billion in 2025 to $59.47 billion by 2026, with a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion can be linked to several factors: an increasing prevalence of type 2 diabetes, a global rise in obesity rates, the development of initial glp-1 receptor agonists, greater public understanding of metabolic syndrome, and the widening scope of endocrinology treatment guidelines.
The glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $101.82 billion by 2030, showing a compound annual growth rate (CAGR) of 14.4%. This expansion during the forecast period can be attributed to factors such as the broadening of cardiometabolic indications beyond diabetes, the increasing uptake of combination incretin therapies, advancements in preventive cardiology approaches, a rising healthcare focus on comorbidities driven by obesity, and the integration of precision medicine into metabolic disease treatment. Major trends expected in the forecast period include the extension of GLP-1 therapies into cardiovascular and chronic kidney disease management, a greater adoption of combination incretin therapies for multi-target cardiometabolic control, the increased use of GLP-1 drugs in programs for reducing obesity-related cardiometabolic risks, the growth of real-world evidence studies validating the long-term cardioprotective benefits of GLP-1 agents, and the growing integration of GLP-1 therapies into digital chronic disease management platforms.
Download A Free Sample Report For Comprehensive Market Insights:
Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Expansion Supported By Key Demand Factors
The increasing occurrence of obesity and diabetes is anticipated to fuel the expansion of the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market in the future. These conditions, obesity and diabetes, are long-term metabolic illnesses characterized by elevated body fat and a compromised capacity for the body to efficiently manage blood glucose. The rise in obesity and diabetes is attributed to diminished physical activity and increasingly sedentary ways of life among populations worldwide. Consequently, the widespread presence of obesity and diabetes is boosting the need for glucagon-like peptide-1 (GLP-1) cardiometabolic therapies, given their efficacy in controlling blood glucose, facilitating weight loss, and enhancing general cardiometabolic well-being. An illustrative example from September 2024, based on data from the Centers for Disease Control and Prevention (CDC), a US-based national public health agency focused on disease prevention and health promotion, showed that 23 US states recorded adult obesity prevalence rates exceeding 35% in 2023, which is an increase from 22 states in 2022. Thus, the increasing incidence of obesity and diabetes is actively propelling the expansion of the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market.
Artificial Intelligence-Powered Supplier Risk Management Market Segment Analysis And Revenue Opportunities
The glucagon-like peptide-1(glp-1) cardiometabolic expansion market covered in this report is segmented –
1) By Drug Type: Glucagon-Like Peptide-1 Receptor Agonists; Glucose-Dependent Insulinotropic Polypeptide Or Glucagon-Like Peptide-1 Dual Agonists; Glucagon-Like Peptide-1 Or Glucose-Dependent Insulinotropic Polypeptide Oral Therapies
2) By Indication: Heart Failure With Preserved Ejection Fraction; Peripheral Artery Disease; Cardiovascular Risk Reduction; Non-Alcoholic Steatohepatitis; Chronic Kidney Disease
3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research Institutes
Subsegments:
1) By Glucagon-Like Peptide-1 Receptor Agonists: Short-Acting Glucagon-Like Peptide-1 Receptor Agonists; Long-Acting Glucagon-Like Peptide-1 Receptor Agonists; Weekly Glucagon-Like Peptide-1 Receptor Agonists; Daily Glucagon-Like Peptide-1 Receptor Agonists
2) By Glucose-Dependent Insulinotropic Polypeptide Or Glucagon-Like Peptide-1 Dual Agonists: Injectable Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists; Oral Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists; Long-Acting Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists
Innovative Receptor Agonist Therapies Strengthening Cardiometabolic Care
Major companies operating in the glucagon-like-peptide (GLP-1) cardiometabolic expansion market are focusing on developing innovative products, such as dual and multi-agonist receptor drugs, to enhance weight reduction outcomes, improve metabolic control, and extend therapeutic benefits beyond diabetes into cardiovascular and obesity-related disease management. Dual and multi-agonist receptor drugs refer to therapies that simultaneously activate two or more hormone receptors, such as GLP-1, GIP, or glucagon receptors, to improve metabolic functions including blood sugar control, weight loss, and energy balance. For instance, in November 2023, Eli Lilly, a US-based pharmaceutical company, launched Zepbound (tirzepatide) in the United States for chronic weight management in adults with obesity or overweight with weight-related comorbidities. This marked the first approval of a dual GIP Or GLP-1 receptor agonist for obesity, significantly expanding the GLP-1 cardiometabolic treatment landscape beyond diabetes into large-scale weight management and metabolic disease intervention.
Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the glucagon-like peptide-1(glp-1) cardiometabolic expansion market are Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca PLC; Boehringer Ingelheim International GmbH; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Zealand Pharma A/S; Innovent Biologics Inc.; Huadong Medicine Co. Ltd.; Hanmi Pharmaceutical Co. Ltd.; Viking Therapeutics Inc.; Structure Therapeutics Inc.; Sciwind Biosciences Co. Ltd.; Ascletis Pharma Inc.; F. Hoffmann-La Roche AG; Pfizer Inc.; Sanofi S.A.; Regeneron Pharmaceuticals Inc.; Eccogene Inc.; Gan & Lee Pharmaceuticals Co. Ltd.; Altimmune Inc.
Access The Complete Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Report:
Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glucagon-like peptide-1(GLP-1) cardiometabolic expansion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.